Dr. Reddys Laboratories Ltd.

Dr Reddys Laboratories is currently trading at Rs. 2113.00, up by 2.60 points or 0.12 % from its previous closing of Rs. 2110.40 on the BSE.

The scrip opened at Rs. 2110.00 and has touched a high and low of Rs. 2128.00 and Rs. 2062.00 respectively. So far 15472 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2400.75 on 15-Jul-2013 and a 52 week low of Rs. 1617.00 on 27-Sep-2012.

Last one week high and low of the scrip stood at Rs. 2215.00 and Rs. 2025.00 respectively. The current market cap of the company is Rs. 35782.42 crore.

The promoters holding in the company stood at 25.53% while Institutions and Non-Institutions held 41.53% and 15.79% respectively.

Pharma major Dr Reddys Laboratories has recalled few lots of Ranitidine Hydrochloride tablets of 150 mg strength in the US earlier this month due to microbial contamination of non-sterile products. It is a class II recall by the company. The drug was supplied to three different parties with three different brand names. The product was manufactured at the company’s facility in Shreveport, USA.

Ranitidine, an over the counter (OTC) drug, is indicated for short-term treatment of active duodenal ulcer and also used to treat heart burn and acid indigestion.

Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.